HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare demonstrated strong financial flexibility at the end of the year, concluding with $1.04 billion in cash and $5.78 billion available under credit facilities, while also increasing its dividend by 8.3% to $0.78 per share. The company's solid growth trajectory is evidenced by a projected EBITDA increase of 7.6%, alongside steady same-store volume growth, supported by investments in high-acuity programs and an expansion in inpatient capacity, with 2026 capital expenditures expected to rise to between $5.0 billion and $5.5 billion. Furthermore, HCA achieved an EBITDA margin of 21.1%, surpassing estimates by 60 basis points, reflecting effective management and operational efficiencies.

The analysis indicates a negative outlook for HCA Healthcare's stock primarily due to declining revenue metrics and anticipated declines in utilization among uninsured patients. Despite a slight increase in same-store adjusted admissions, the company's revenue per adjusted admission fell below both internal estimates and consensus expectations, signaling potential revenue pressures. Additionally, guidance forecasts a significant decline in Medicaid supplementalDisproportionate Share Payments (DPP) and a projected 30% decrease in utilization of care for uninsured patients, further complicating revenue growth prospects and raising concerns about the firm's operational stability.